Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 4
1991 3
1992 3
1993 17
1994 19
1995 21
1996 44
1997 46
1998 43
1999 66
2000 74
2001 62
2002 80
2003 79
2004 76
2005 91
2006 78
2007 87
2008 80
2009 75
2010 83
2011 69
2012 64
2013 79
2014 73
2015 82
2016 88
2017 60
2018 58
2019 51
2020 46
2021 33
2022 21
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

1,698 results

Results by year

Filters applied: . Clear all
Page 1
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group. Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing the annual rat …
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group …
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial.
Kliewer KL, Gonsalves N, Dellon ES, Katzka DA, Abonia JP, Aceves SS, Arva NC, Besse JA, Bonis PA, Caldwell JM, Capocelli KE, Chehade M, Cianferoni A, Collins MH, Falk GW, Gupta SK, Hirano I, Krischer JP, Leung J, Martin LJ, Menard-Katcher P, Mukkada VA, Peterson KA, Shoda T, Rudman Spergel AK, Spergel JM, Yang GY, Zhang X, Furuta GT, Rothenberg ME. Kliewer KL, et al. Lancet Gastroenterol Hepatol. 2023 May;8(5):408-421. doi: 10.1016/S2468-1253(23)00012-2. Epub 2023 Feb 28. Lancet Gastroenterol Hepatol. 2023. PMID: 36863390 Free PMC article. Clinical Trial.
Individuals without histological response to 1FED could proceed to 6FED, and those without histological response to 6FED could proceed to swallowed topical fluticasone propionate 880 mug twice per day (with unrestricted diet), for 6 weeks. ...For patients without histologi …
Individuals without histological response to 1FED could proceed to 6FED, and those without histological response to 6FED could proceed to sw …
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ, Martin PJ, Storer BE, Inamoto Y, Chai X, Flowers MED, Lee SJ. Williams KM, et al. Biol Blood Marrow Transplant. 2016 Apr;22(4):710-716. doi: 10.1016/j.bbmt.2015.10.009. Epub 2015 Oct 22. Biol Blood Marrow Transplant. 2016. PMID: 26475726 Free PMC article. Clinical Trial.
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT) is associated with high mortality. We hypothesized that inhaled fluticasone, azithromycin, and montelukast (FAM) with a brief steroid pulse could avert progression of new-onse …
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT) is associated with high mortality. We hypo …
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT, Deans A, Mehta R, Sousa AR. Daley-Yates PT, et al. Pulm Pharmacol Ther. 2022 Dec;77:102171. doi: 10.1016/j.pupt.2022.102171. Epub 2022 Oct 13. Pulm Pharmacol Ther. 2022. PMID: 36243386 Clinical Trial.
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF). METHODS: Study 1: Fourteen healthy participants received inhaled and intraven …
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), flutic
Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression.
Daley-Yates P, Brealey N, Thomas S, Austin D, Shabbir S, Harrison T, Singh D, Barnes N. Daley-Yates P, et al. Br J Clin Pharmacol. 2021 Feb;87(2):483-493. doi: 10.1111/bcp.14406. Epub 2020 Jun 17. Br J Clin Pharmacol. 2021. PMID: 32484940 Free PMC article. Clinical Trial.
Each treatment period comprised five 7-day dose escalations (mug/d): fluticasone furoate (FF; 25 100 200 400 800), fluticasone propionate (FP; 50 200 500 1000 2000), budesonide (BUD; 100 400 800 1600 3200) or placebo. ...
Each treatment period comprised five 7-day dose escalations (mug/d): fluticasone furoate (FF; 25 100 200 400 800), fluticasone
Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis.
Hirano I, Safroneeva E, Roumet MC, Comer GM, Eagle G, Schoepfer A, Falk GW. Hirano I, et al. Aliment Pharmacol Ther. 2020 Apr;51(8):750-759. doi: 10.1111/apt.15670. Epub 2020 Mar 9. Aliment Pharmacol Ther. 2020. PMID: 32149424 Clinical Trial.
BACKGROUND: APT-1011, a fluticasone propionate orally disintegrating tablet formulation, is under investigation for the treatment of eosinophilic oesophagitis (EoE). ...
BACKGROUND: APT-1011, a fluticasone propionate orally disintegrating tablet formulation, is under investigation for the treatment of …
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
Feldman WB, Kesselheim AS, Avorn J, Russo M, Wang SV. Feldman WB, et al. Ann Intern Med. 2023 Aug;176(8):1047-1056. doi: 10.7326/M23-0615. Epub 2023 Aug 8. Ann Intern Med. 2023. PMID: 37549393 Clinical Trial.
Food and Drug Administration (FDA) approved the first generic maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD). The inhaler, Wixela Inhub (fluticasone-salmeterol; Viatris), is a substitutable version of the dry powder inhaler Advair Diskus ( …
Food and Drug Administration (FDA) approved the first generic maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD …
Comparing Budesonide and Fluticasone Propionate in Children with Moderate to Severe Asthma: A Pilot Randomized Controlled Trial.
Sadeghzadeh M, Khoshnevisasl P, Ahmadiafshar A, Motamed N, Pourmarjani A. Sadeghzadeh M, et al. Iran J Allergy Asthma Immunol. 2023 Dec 28;22(6):527-535. doi: 10.18502/ijaai.v22i6.14642. Iran J Allergy Asthma Immunol. 2023. PMID: 38477950 Free article. Clinical Trial.
Additionally, the requirement for salbutamol use was notably reduced in the fluticasone group compared to the budesonide group throughout all three months. The efficacy of fluticasone propionate in decreasing the need for rescue medication and enhancing asthma contr …
Additionally, the requirement for salbutamol use was notably reduced in the fluticasone group compared to the budesonide group throug …
Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma.
Oppenheimer J, Hanania NA, Chaudhuri R, Sagara H, Bailes Z, Fowler A, Peachey G, Pizzichini E, Slade D. Oppenheimer J, et al. Chest. 2023 Nov;164(5):1087-1096. doi: 10.1016/j.chest.2023.06.029. Epub 2023 Jun 27. Chest. 2023. PMID: 37385337 Free article. Clinical Trial.
STUDY DESIGN AND METHODS: This post hoc analysis used trough FEV(1) data from the randomized double-anonymized parallel-group phase 3A CAPTAIN (205715; NCT02924688) and phase 2B 205832 (NCT03012061) trials in patients with uncontrolled asthma. CAPTAIN evaluated the impact of addi …
STUDY DESIGN AND METHODS: This post hoc analysis used trough FEV(1) data from the randomized double-anonymized parallel-group phase 3A CAPTA …
Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial.
Hale EM, Greene G, Mulvey C, Mokoka MC, van Boven JFM, Cushen B, Sulaiman I, Brennan V, Lombard L, Walsh J, Plunkett S, McCartan TA, Kerr PJ, Reilly RB, Hughes C, Kent BD, Jackson DJ, Butler M, Counihan I, Hayes J, Faul J, Kelly M, Convery R, Nanzer AM, Fitzgerald JM, Murphy DM, Heaney LG, Costello RW; INCA Research Team. Hale EM, et al. Lancet Respir Med. 2023 Jul;11(7):591-601. doi: 10.1016/S2213-2600(22)00534-3. Epub 2023 Mar 21. Lancet Respir Med. 2023. PMID: 36963417 Clinical Trial.
Three (16%) of 19 active and 11 (44%) of 25 control patients increased their medication from fluticasone propionate 500 mug daily to 1000 mug daily (500 mug twice a day; adjusted OR 0.23 [0.06-0.87], p=0.026). 26 (31%) of 83 active and 13 (18%) of 73 controls reduced their …
Three (16%) of 19 active and 11 (44%) of 25 control patients increased their medication from fluticasone propionate 500 mug daily to …
1,698 results